Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis

Cancer Cell

Volumn 2, Issue 6, 2002, Pages 451-461

  Moody, Susan E ^a,b   Sarkisian, Christopher J ^a,b   Hahn, Kristina T ^a,b   Gunther, Edward J ^a,b   Pickup, Steven ^a   Dugan, Katherine D ^a,b   Innocent, Nathalie ^a,b   Cardiff, Robert D ^c   Schnall, Mitchell D ^a   Chodosh, Lewis A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; DOXYCYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER INVASION; CANCER RECURRENCE; CANCER REGRESSION; CONTROLLED STUDY; DISEASE COURSE; GENE ACTIVATION; GENE EXPRESSION; LUNG METASTASIS; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TRANSGENIC MOUSE; ADENOCARCINOMA; ANIMAL; CANCER TRANSPLANTATION; CELL TRANSFORMATION; DOWN REGULATION; EPITHELIUM; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; METASTASIS; METHODOLOGY; NICK END LABELING; NORTHERN BLOTTING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; PROTO ONCOGENE; REMISSION; TRANSGENE; UDDER;

ANIMALIA; MOUSE MAMMARY TUMOR VIRUS; MUS MUSCULUS;

ADENOCARCINOMA; ANIMALS; BLOTTING, NORTHERN; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; DOXYCYCLINE; EPITHELIUM; FEMALE; GENE EXPRESSION REGULATION; GENES, ERBB-2; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; NEOPLASM TRANSPLANTATION; REMISSION INDUCTION; TRANSGENES;

EID: 19044370434     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00212-X     Document Type: Article

References (26)

1. Bargmann, C.I., Hung, M.C., and Weinberg, R.A. (1986). Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45, 649-657.
2. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C.C., Dantis, L., Sklarin, N.T., Seidman, A.D., Hudis, C.A., Moore, J., et al. (1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14, 737-744.
3. Berger, M.S., Locher, G.W., Saurer, S., Gullick, W.J., Waterfield, M.D., Groner, B., and Hynes, N.E. (1988). Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 48, 1238-1243.
4. Bouchard, L., Lamarre, L., Tremblay, P.J., and Jolicoeur, P. (1989). Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57, 931-936.
5. Cardiff, R.D., and Muller, W.J. (1993). Transgenic mouse models of mammary tumorigenesis. Cancer Surv. 16, 97-113.
6. Cardiff, R.D., and Wellings, S.R. (1999). The comparative pathology of human and mouse mammary glands. J. Mammary Gland Biol. Neoplasia 4, 105-122.
7. Cardiff, R.D., Anver, M.R., Gusterson, B.A., Hennighausen, L., Jensen, R.A., Merino, M.J., Rehm, S., Russo, J., Tavassoli, F.A., Wakefield, L.M., et al. (2000). The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 19, 968-988.
8. Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999). Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468-472.
9. Cobleigh, M.A., Vogel, C.L., Tripathy, D., Robert, N.J., Scholl, S., Fehrenbacher, L., Wolter, J.M., Paton, V., Shak, S., Lieberman, G., and Slamon, D.J. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648.
10. D'Cruz, C.M., Gunther, E.J., Boxer, R.B., Hartman, J.L., Sintasath, L., Moody, S.E., Cox, J.D., Ha, S.I., Belka, G.K., Golant, A., et al. (2001). c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat. Med. 7, 235-239.
11. Felsher, D.W., and Bishop, J.M. (1999). Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4, 199-207.
12. Fisher, G.H., Wellen, S.L., Klimstra, D., Lenczowski, J.M., Tichelaar, J.W., Lizak, M.J., Whitsett, J.A., Koretsky, A., and Varmus, H.E. (2001). Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15, 3249-3262.
13. Gunther, E.J., Belka, G.K., Wertheim, G.B., Wang, J., Hartman, J.L., Boxer, R.B., and Chodosh, L.A. (2002). A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J. 16, 283-292.
14. Guy, C.T., Webster, M.A., Schaller, M., Parsons, T.J., Cardiff, R.D., and Muller, W.J. (1992). Expression of the c-neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 89, 10578-10582.
15. Hortobagyi, G.N. (2001). Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin. Oncol. 28, 43-47.
16. Huettner, C.S., Zhang, P., Van Etten, R.A., and Tenen, D.G. (2000). Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat. Genet. 24, 57-60.
17. Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonhardt, E., Trinh, M., Sundberg, C.D., Bishop, J.M., and Felsher, D.W. (2002). Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297, 102-104.
18. Maglione, J.E., Moghanaki, D., Young, L.J., Manner, C.K., Ellies, L.G., Joseph, S.O., Nicholson, B., Cardiff, R.D., and MacLeod, C.L. (2001). Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res. 61, 8298-8305.
19. Muller, W.J., Sinn, E., Pattengale, P.K., Wallace, R., and Leder, P. (1988). Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54, 105-115.
20. Pelengaris, S., Khan, M., and Evan, G.I. (2002). Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109, 321-334.
21. Rajan, J.V., Wang, M., Marquis, S.T., and Chodosh, L.A. (1996). Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc. Natl. Acad. Sci. USA 93, 13078-13083.
22. Slamon, D.J., Clark, G.M., and Wong, S.G. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
23. Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792.
24. Vogel, C.L., Cobleigh, M.A., Tripathy, D., Gutheil, J.C., Harris, L.N., Fehrenbacher, L., Slamon, D.J., Murphy, M., Novotny, W.F., Burchmore, M., Shak, S., Stewart, S.J., and Press, M. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-26.
25. Wang, S.C., and Hung, M.C. (2001). HER2 overexpression and cancer targeting. Semin. Oncol. 28, 115-124.
26. Wang, S.C., Zhang, L., Hortobagyi, G.N., and Hung, M.C. (2001). Targeting HER2: recent developments and future directions for breast cancer patients. Semin. Oncol. 28, 21-29.